OCUL
Ocular Therapeutix Inc
10.50$
+5.1%
vs. previous close
Closing price · As of: Sep 22, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 97.4% | 97.0% | 93.3% | 78.2% | 76.9% | 76.4% | 94.0% | 93.4% | 86.8% | 92.1% | 96.3% | 96.8% | |
| 47.8% | 27.9% | 44.0% | 74.9% | 74.0% | 69.1% | 87.1% | 80.1% | 68.5% | 77.7% | 85.6% | 91.2% | |
| 95.7% | 95.2% | 90.9% | 74.9% | 74.0% | 69.1% | 87.1% | 80.1% | 68.5% | 77.7% | 85.6% | 91.2% | |
| 0.4% | 0.2% | 0.3% | 0.4% | 0.3% | 3.2% | 4.7% | 10.3% | 14.3% | 10.4% | 7.1% | 3.8% | |
| 0.2% | 0.1% | 0.2% | 0.2% | 0.3% | 1.2% | 0.5% | 0.6% | 1.3% | 0.9% | 0.7% | 0.4% | |
| 2.3% | 2.8% | 4.4% | 18.9% | 14.0% | 12.9% | 3.1% | 5.8% | 6.6% | – | – | – | |
| 0.0% | 0.0% | 0.0% | 0.0% | – | – | – | – | – | – | – | – | |
| 0.0% | 0.0% | 0.0% | 0.0% | – | – | – | – | – | – | – | – | |
| 24.9% | 18.8% | 30.6% | 52.8% | 50.9% | 104.6% | 70.9% | 57.0% | 76.3% | 63.8% | 31.1% | 19.0% | |
| 7.5% | 4.9% | 11.1% | 24.2% | 12.5% | 15.3% | 10.2% | 12.9% | 21.0% | 13.8% | 9.0% | 6.3% | |
| 1.7% | 13.8% | 2.1% | 10.0% | – | 1.4% | 3.7% | 0.8% | 1.1% | 0.6% | 0.4% | 0.3% | |
| 1.7% | 1.8% | 2.8% | 6.4% | 4.1% | 4.2% | 1.0% | 2.2% | 3.4% | 1.7% | 0.9% | 0.5% | |
| 17.3% | 13.8% | 18.8% | 22.5% | 33.9% | 62.6% | 15.7% | 25.1% | 36.2% | 29.7% | 15.0% | 8.8% | |
| 75.1% | 81.2% | 69.4% | 47.2% | 49.1% | -4.6% | 29.1% | 43.0% | 23.7% | 36.2% | 68.9% | 81.0% | |
| -114.4% | -117.1% | -232.0% | -428.0% | -406.9% | -487.2% | -205.9% | -266.4% | -413.2% | -276.8% | -194.6% | -143.2% | |
| 13.6% | 21.1% | 33.1% | 52.0% | 52.2% | 57.5% | 23.2% | 40.1% | 55.4% | 34.0% | 34.6% | 23.2% |
Data as of: September 22, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.